Haemodynamic performance and clinical outcomes of transcatheter aortic valve replacement with the self-expanding ACURATE neo2

Andrea Scotti, Matteo Pagnesi, Won Keun Kim, Ulrich Schäfer, Marco Barbanti, Giuliano Costa, Sara Baggio, Matteo Casenghi, Federico De Marco, Maarten Vanhaverbeke, Lars Sondergaard, Alexander Wolf, Joachim Schofer, Marco Bruno Ancona, Matteo Montorfano, Ran Kornowski, Hana Vaknin Assa, Stefan Toggweiler, Alfonso Ielasi, David Hildick-SmithStephan Windecker, Albrecht Schmidt, Andrea Buono, Diego Maffeo, Dimytri Siqueira, Francesco Giannini, Marianna Adamo, Mauro Massussi, David A. Wood, Jan Malte Sinning, Jan Van Der Heyden, Dirk Jan van Ginkel, Nicholas Van Mieghem, Verena Veulemans, Darren Mylotte, Vasileios Tzalamouras, Maurizio Taramasso, Rodrigo Estévez-Loureiro, Antonio Colombo, Antonio Mangieri, Azeem Latib

Research output: Contribution to journalArticleAcademicpeer-review

17 Citations (Scopus)


BACKGROUND: Transcatheter aortic valve replacement (TAVR) with the ACURATE neo device has been associated with a non-negligible incidence of paravalvular aortic regurgitation (AR). The new-generation ACURATE neo2 has been designed to mitigate this limitation. AIMS: The aim of the study was to compare TAVR with the ACURATE neo and neo2 devices. METHODS: The NEOPRO and NEOPRO-2 registries retrospectively included patients undergoing transfemoral TAVR with self-expanding valves at 24 and 20 centres, respectively. Patients receiving the ACURATE neo and neo2 devices (from January 2012 to December 2021) were included in this study. Predischarge and 30-day VARC-3 defined outcomes were evaluated. The primary endpoint was predischarge moderate or severe paravalvular AR. Subgroup analyses per degree of aortic valve calcification were performed. RESULTS: A total of 2,026 patients (neo: 1,263, neo2: 763) were included. Predischarge moderate or severe paravalvular AR was less frequent for the neo2 group (2% vs 5%; p<0.001), resulting in higher VARC-3 intended valve performance (96% vs 90%; p<0.001). Furthermore, more patients receiving the neo2 had none/trace paravalvular AR (59% vs 38%; p<0.001). The reduction in paravalvular AR with neo2 was mainly observed with heavy aortic valve calcification. New pacemaker implantation and VARC-3 technical and device success rates were similar between the 2 groups; there were more frequent vascular and bleeding complications for the neo device. Similar 1-year survival was detected after TAVR (neo2: 90% vs neo: 87%; p=0.14). CONCLUSIONS: TAVR with the ACURATE neo2 device was associated with a lower prevalence of moderate or severe paravalvular AR and more patients with none/trace paravalvular AR. This difference was particularly evident with heavy aortic valve calcification.

Original languageEnglish
Pages (from-to)804-811
Number of pages8
JournalEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
Issue number10
Publication statusPublished - 18 Nov 2022

Bibliographical note

Publisher Copyright:
© Europa Digital & Publishing 2022. All rights reserved.


Dive into the research topics of 'Haemodynamic performance and clinical outcomes of transcatheter aortic valve replacement with the self-expanding ACURATE neo2'. Together they form a unique fingerprint.

Cite this